Press Release 6 July 2018
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Sativa Investments PLC
(“Sativa” or “the Company”)
The Board of Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, is aware of the exceptional and growing demand amongst investors to own shares in the Company. As announced on the Company’s admission to trading on the NEX Exchange Growth Market on 29 March 2018 (“Admission”), all investors who subscribed for Ordinary Shares in the Company at Admission entered into an Orderly Market Agreement and the Directors of Sativa agreed, should demand arise, to exercise their allocated options and sell the resulting Ordinary Shares through the Company’s NEX Exchange Corporate Adviser and Broker, Peterhouse Capital Limited (“Peterhouse”).
However, given the unprecedented demand in the market for the Ordinary Shares in the Company, and the desire of the Sativa Directors not to have to be the sole suppliers of such shares at levels which the Board believes do not reflect the long-term value of the Company, the Board has agreed to a refinement of the Orderly Market Agreements entered into at the time of Admission. Therefore, with immediate effect, all shareholders who are subject to the current Orderly Market Agreements will be permitted to trade in the Ordinary Shares of the Company with the consent of Peterhouse, such consent not to be unreasonably withheld.
Pursuant to the NEX Exchange Growth Market Rules for Investors, the Directors remain subject to the Lock-In Agreements entered into on Admission, but they will no longer be required to make further shares available through the exercise of their options.
The Directors of the Company accept responsibility for the contents of this announcement.
– Ends –
For further information please contact:
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
NEX Exchange Corporate Adviser
Peterhouse Capital Limited
+44 (0) 20 7469 0930
Notes to Editors
Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.
The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa intends to acquire can either be public or private. Sativa Investments’ first two deals include Canadian-based, tri-listed, emerging global pharmaceutical company, Veritas Pharma Inc., and Toronto-based Pharma-Tech company that owns the patent-pending proprietary QuickStrip™ technology, Rapid Dose Therapeutics Inc.
The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.
For more information on Sativa Investments, please visit: https://sativainvestments.com/